Portfolio News
Sofinnova Crossover & Sofinnova Industrial Biotech
Synthace Launches Ground-Breaking New Whitepaper: Computer-Aided Biology: Delivering Biotechnology in the 21st Century
Synthace Launches Ground-Breaking New Whitepaper: Computer-Aided Biology: Delivering Biotechnology in the 21st Century
Related Company
SynthaceRelated Strategy
CrossoverRelated Strategy
Industrial BiotechRelated Deal lead
Joško BobanovićComprehensive report heralds the beginning of Computer Aided Biology (CAB)
October 01, 2018 LONDON-Synthace Ltd., the company behind the leading cloud software platform for automating and improving the success rate of biological research and development, is pleased to announce it has released a new comprehensive whitepaper entitled, Computer Aided Biology: Delivering Biotechnology in the 21st Century.
According to the report, Computer Aided Biology is a conceptual framework, around which there is an emerging ecosystem of tools that collectively transform how we approach biological research, development, and manufacturing. Computer Aided Biology is comprised of two domains: the digital and the physical. The Digital, powered by artificial intelligence includes software for the design and simulation of biological systems, as well as methods of collating, connecting, structuring, and analysing data. The Physical, enabled by automation, includes systems that allow for the seamless transfer of simulated biological designs and processes via abstracted experimental design, simulation, and automated physical execution. Only by connecting the entire tools ecosystem, and enabling an integrated loop, will scientists be able to address the challenges of 21st century biology.
This transformation of how people work, enabled by Computer Aided Biology, mirrors revolutions that have already changed how other industries, including semiconductors, automotive, and aerospace foundationally operate. The report delves into what can be learned from how those revolutions played out, as well as acknowledging the unique challenges that flow from the sheer complexity of biological systems.
"We're pleased to offer these insights and approach," said Tim Fell, CEO Synthace. "In this ground-breaking whitepaper, we highlight how the emerging Computer Aided Biology ecosystem is evolving, and how companies from the technology and life science domains are coming together to make biology a true engineering discipline."
"This whitepaper also shows that Synthace is a leading organisation helping researchers and manufacturers integrate the physical, digital and biological realms, the synergy of which is at the heart of the fourth industrial revolution," Fell concluded.
The full detailed whitepaper can be found on the following link: https://synthace.com/computer-aided-biology-whitepaper
About Synthace
Based in London, Synthace is developing Antha, a language and software platform specifically for biology that lets researchers aim higher and achieve better results, faster. Antha is designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment. With customers across pharma, agritech and industrial biotechnology Synthace has been recognised by the World Economic Forum as a Technology Pioneer that is helping shape the Fourth Industrial Revolution – a technological revolution that will fundamentally alter the way we live, work and relate to one another. For more information, visit: www.synthace.com.
Contacts
Synthace
Bobby Brill
Press@synthace.com
+44 7867488769
Related News
Cure51 Launches NHS-Approved Study With Cambridge University Hospitals and Seven Other Leading UK Oncology Institutions to Unlock Cancer Survival Secrets
BrightHeart Secures FDA Clearance for First AI Software Revolutionizing Prenatal Fetal Heart Ultrasound Evaluations
Elicit Plant announces €45 Million Investment Round to Accelerate Global Expansion
TechBio startup Cure51 selects 10x Genomics Visium HD for new drug discovery initiative
Noema Pharma announces first patients dosed in Phase 2b study with Gemlapodect (NOE-105), a first-in-class investigational therapy for Tourette Syndrome